We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-7.11%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$237M
AUM Growth
-$388M
Cap. Flow
-$385M
Cap. Flow %
-162.18%
Top 10 Hldgs %
53.02%
Holding
76
New
17
Increased
16
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
ESTA icon
Establishment Labs
ESTA
+$11.8M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$4.31M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.26M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.84M
5
LNTH icon
Lantheus
LNTH
+$1.58M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$13.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.1M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.98M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$5.96M
5
AZN icon
AstraZeneca
AZN
+$4.92M

Sector Composition

Rank Sector Weight
1 Healthcare 63.86%
2 Financials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESTA icon
1
Establishment Labs
ESTA
$2.72B
$19.6M 8.25%
359,956
+185,456
+106% +$11.8M
KURA icon
2
Kura Oncology
KURA
$964M
$17M 7.17%
928,256
+4,109
+0.4% +$59.1K
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$16.4M 6.91%
937,568
+92,413
+11% +$1.45M
NARI
4
DELISTED
Inari Medical, Inc. Common Stock
NARI
$15.1M 6.37%
222,173
+2,173
+1% +$156K
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$11.6M 4.9%
125,087
+5,087
+4% +$479K
LLY icon
6
CALL
Eli Lilly
LLY
$1.05T
$9.73M 4.1%
+30,000
New +$9.01M
LNTH icon
7
Lantheus
LNTH
$7B
$9.24M 3.9%
140,000
+25,000
+22% +$1.58M
ESTA icon
8
PUT
Establishment Labs
ESTA
$2.72B
$8.16M 3.44%
+150,000
New +$9.52M
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$12.8B
$7.16M 3.02%
100,000
+25,000
+33% +$1.84M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.98M 2.52%
75,000
+45,000
+150% +$4.26M
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.69M 2.4%
45,000
+37,500
+500% +$4.31M
KRTX
12
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.69M 2.4%
+45,000
New +$5.17M
AZN icon
13
AstraZeneca
AZN
$262B
$5.62M 2.37%
42,500
-37,500
-47% -$4.92M
MORF
14
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4.68M 1.97%
215,723
-249,931
-54% -$6.98M
NVAX icon
15
PUT
Novavax
NVAX
$1.35B
$4.63M 1.95%
+90,000
New +$4.66M
LNTH icon
16
PUT
Lantheus
LNTH
$7B
$4.62M 1.95%
70,000
+30,000
+75% +$1.89M
BLU
17
DELISTED
BELLUS Health Inc.
BLU
$4.56M 1.92%
493,278
-106,722
-18% -$873K
RPTX
18
DELISTED
Repare Therapeutics
RPTX
$4.49M 1.89%
321,200
-147,705
-31% -$1.74M
NVAX icon
19
CALL
Novavax
NVAX
$1.35B
$4.37M 1.84%
+85,000
New +$4.4M
CRSP icon
20
CALL
CRISPR Therapeutics
CRSP
$4.71B
$4.25M 1.79%
70,000
+15,000
+27% +$882K
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
$4.05M 1.71%
1,372,244
+100,000
+8% +$239K
CLDX icon
22
CALL
Celldex Therapeutics
CLDX
$2.77B
$3.91M 1.65%
+145,000
New +$4.21M
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$376M
$3.45M 1.45%
250,466
-49,534
-17% -$590K
ARYE
24
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$3.43M 1.44%
352,500
-350,000
-50% -$3.4M
LEGN icon
25
CALL
Legend Biotech
LEGN
$4.31B
$2.75M 1.16%
+50,000
New +$2.11M
1
2 3

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Affinity Asset Advisors held 76 positions worth $237M, down 62% from $625M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Affinity Asset Advisors withdrew a net $385M in Q2 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $13.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 34% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arcellx worth $1.36M.

  • Affinity Asset Advisors's largest Q2 2022 buy was Arcellx: 75,000 shares worth $1.36M.
  • Affinity Asset Advisors added most to Establishment Labs in Q2 2022, an estimated $11.8M increase.
  • Affinity Asset Advisors's biggest Q2 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $6.98M.
  • Affinity Asset Advisors fully exited SpringWorks Therapeutics in Q2 2022, selling an estimated $13.9M.
  • Affinity Asset Advisors's ten largest holdings make up 53% of its $237M portfolio in Q2 2022.
  • Affinity Asset Advisors opened 17 new positions and closed 22 in Q2 2022.
  • Affinity Asset Advisors's portfolio value fell 62% quarter-over-quarter to $237M.

Based on Affinity Asset Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.